LENZ Therapeutics, Inc. (NASDAQ:LENZ) Shares Acquired by BBR Partners LLC

BBR Partners LLC boosted its position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) by 100.0% in the third quarter, Holdings Channel.com reports. The firm owned 40,000 shares of the company’s stock after acquiring an additional 20,000 shares during the quarter. BBR Partners LLC’s holdings in LENZ Therapeutics were worth $950,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in the business. American International Group Inc. acquired a new stake in shares of LENZ Therapeutics in the 1st quarter valued at approximately $44,000. SG Americas Securities LLC acquired a new position in LENZ Therapeutics during the third quarter worth $107,000. Squarepoint Ops LLC purchased a new position in LENZ Therapeutics in the second quarter worth $181,000. MetLife Investment Management LLC acquired a new stake in LENZ Therapeutics in the third quarter valued at $182,000. Finally, GSA Capital Partners LLP purchased a new stake in shares of LENZ Therapeutics during the 3rd quarter worth $246,000. Hedge funds and other institutional investors own 54.32% of the company’s stock.

LENZ Therapeutics Price Performance

LENZ Therapeutics stock opened at $37.30 on Thursday. LENZ Therapeutics, Inc. has a fifty-two week low of $14.42 and a fifty-two week high of $38.93. The stock has a fifty day moving average of $28.20 and a two-hundred day moving average of $22.98.

LENZ Therapeutics (NASDAQ:LENZ) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.09. During the same period in the previous year, the firm posted ($1.33) EPS. Research analysts predict that LENZ Therapeutics, Inc. will post -2.09 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on LENZ. Piper Sandler reiterated an “overweight” rating and issued a $36.00 price target on shares of LENZ Therapeutics in a report on Thursday, August 15th. HC Wainwright restated a “buy” rating and set a $38.00 target price on shares of LENZ Therapeutics in a research report on Thursday, November 7th. William Blair upgraded shares of LENZ Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. Finally, Raymond James initiated coverage on LENZ Therapeutics in a research note on Friday, September 27th. They set an “outperform” rating and a $37.00 price target on the stock. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $35.40.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.